adesso (ADN1) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
15 May, 2026Executive summary
Achieved 14% organic sales growth to approximately EUR 1.3 billion in 2024, outpacing market growth and supported by international expansion.
EBITDA rose 23% year-over-year to EUR 98.3 million (excluding one-off effects), with margin improving to 7.6% and H2 margin reaching 10.6%.
Net income increased to EUR 10.2 million, up 199% from near zero last year; earnings per share rose 155% to EUR 1.25.
Share buyback program completed, acquiring 1.9% of shares for EUR 10 million, supporting share price growth.
Dividend proposal increased from EUR 0.17 to EUR 0.75 per share for 2024.
Financial highlights
Sales grew 14% year-over-year to EUR 1,297.0 million in 2024, driven almost entirely by organic growth.
EBITDA margin improved to 7.6% (excluding one-off effects), with operating cash flow up 44% to EUR 110.6 million.
Free cash flow per share improved to EUR 6.92, with total free cash flow reaching EUR 45.1 million, up 217% year-over-year.
Net working capital reduced by 8% to EUR 162.8 million; net debt decreased slightly by EUR 2 million to EUR 46.6 million.
Return on equity averaged 12.4% over five years; 2024 ROE at 5.3%.
Outlook and guidance
2025 revenue guidance set at EUR 1.35–1.45 billion, implying 4–12% growth; EBITDA forecasted at EUR 105–125 million, with margin expected to exceed 8%.
Public sector expected to recover in H2 2025 after a slow start due to delayed budgets.
Ongoing market demand in IT services anticipated despite recessionary environment.
Dividend proposal increased to EUR 0.75 per share.
Latest events from adesso
- 12% sales growth and 34% EBITDA increase in H1 2025, with guidance reaffirmed and margin gains.ADN1
Q2 202515 May 2026 - Q1 2026 revenue up 13%, EBITDA up 58%, and net earnings positive amid strong sector growth.ADN1
Q1 202611 May 2026 - 2025 sales rose 14% to EUR 1.47B, with 30% EBITDA growth and a strong 2026 outlook.ADN1
Q4 202531 Mar 2026 - Sales up 11% with margin pressure; H2 2025 expected to drive earnings recovery.ADN1
Q1 2025 TU3 Feb 2026 - Sales up 16% to €631.1m, but negative EPS and lower EBITDA guidance due to margin pressure.ADN1
H1 20241 Feb 2026 - Record sales and profitability in Q3 2024, with strong outlook and share buyback underway.ADN1
Q3 2024 TU14 Jan 2026 - Sales, EBITDA, and EPS surged, with robust sector growth and guidance at the upper end.ADN1
Q3 202515 Nov 2025